The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.
about
Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discoveryFrom basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research"Remote Ischemic Perconditioning to Reduce Reperfusion Injury During Acute ST-Segment-Elevation Myocardial Infarction: A Systematic Review and Meta-AnalysisCardioprotection: Where to from here?Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at riskGinsenoside Rg3 Improves Cardiac Function after Myocardial Ischemia/Reperfusion via Attenuating Apoptosis and Inflammation.Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodelingThe Role for Cardiovascular Remodeling in Cardiovascular Outcomes.SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.Cardioprotection by remote ischemic conditioning and its signal transduction.Implication of the neurotrophin receptor p75NTR in vascular diseases: beyond the eye.Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning.Challenges of Translational Science.Heart Repair Using Nanogel-Encapsulated Human Cardiac Stem Cells in Mice and Pigs with Myocardial Infarction.Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.STAT3 as a common signal of ischemic conditioning: a lesson on "rigor and reproducibility" in preclinical studies on cardioprotection.Sanggenon C protects against cardiomyocyte hypoxia injury by increasing autophagy.The RISK pathway and beyond.Pre- and postconditioning the heart with hydrogen sulfide (H2S) against ischemia/reperfusion injury in vivo: a systematic review and meta-analysis.Cardiac troponins: from myocardial infarction to chronic disease.MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase Cepsilon.Molecular imaging of cardiac remodelling after myocardial infarction.The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions.Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury.Ginsenoside Rb1 for Myocardial Ischemia/Reperfusion Injury: Preclinical Evidence and Possible Mechanisms.Guidelines for Experimental Models of Myocardial Ischemia and Infarction.Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins.Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype.Fast therapeutic hypothermia prevents post-cardiac arrest syndrome through cyclophilin D-mediated mitochondrial permeability transition inhibition.The Natural Flavone Acacetin Confers Cardiomyocyte Protection Against Hypoxia/Reoxygenation Injury via AMPK-Mediated Activation of Nrf2 Signaling Pathway.When the situation almost cannot be worse…Fasudil, a Rho-Kinase Inhibitor, Exerts Cardioprotective Function in Animal Models of Myocardial Ischemia/Reperfusion Injury: A Meta-Analysis and Review of Preclinical Evidence and Possible MechanismsPractical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection
P2860
Q28072918-6390B158-313D-47BD-A20E-2D94393B00C6Q28073354-B543B308-843D-481F-A967-EC76E9028872Q29994485-15E7C9B1-46D2-4183-B196-B413A1D062C7Q30244797-DE94959E-F340-45AF-BE2D-E1EE10D98C93Q33721171-20E9F2D8-90A3-46C2-A8F2-61F8E384A24DQ37571651-4A4C775A-77E1-488F-B2F6-86C88E96A104Q37680021-29E7C380-BD36-4F99-8798-82B32551F65CQ37683942-F1A03230-6532-4B9A-B9F1-985B4076346FQ38867740-D2BB1BC3-DD4F-4C22-9E59-173C2DCAA809Q38922001-7AB2ACE7-C9AC-4C2E-B4CA-007E424B7633Q39032510-1993A743-897D-487C-813E-F7A58ABD393DQ42286938-80A6CAD5-623D-4447-8559-F3A0E9B20C7CQ42318959-844B84FE-CE19-4E97-8E2A-47B347790659Q42346379-790666C4-6BB2-4FF5-A306-67518D7ABCE6Q42628519-A61279FA-B6F7-4355-A576-8673CB53FE43Q46120439-6801207C-51CA-4254-AA94-1BE1704405ACQ46257421-787B5ACF-A03F-4D89-A685-63A8C14D2BFEQ46293355-84893D82-FDEF-49EA-A0BF-115F0AF868B9Q47100578-104E78CB-9214-4F2C-B637-16DEE73EC974Q47141923-F21697F5-C53F-4654-B357-AC1C8AAD7C63Q47671109-AE08E94C-124C-43F6-9EBC-CD59CB533A9EQ47830657-12AE76EB-41A6-436D-89B0-6809C832137AQ48221861-C849D8C9-812A-4226-A2FB-29BB7D06E808Q48649274-6560D495-9518-46DF-91CF-B7C4912C8720Q48660344-E534F980-7232-4194-A655-04C0D4EEA285Q49515494-F5B4E470-CBB4-4064-B2C3-85DD5FC378B4Q49917885-AF2C29DA-7D94-440E-8393-600A3C1A91A5Q50560471-0E42C540-CF33-4147-B178-BBFFF3C5CC5CQ50964118-9C917649-37C8-4A90-90D9-21417C955F16Q51009258-45062140-3064-4ACC-9D66-D7EE1E0DB8F9Q55253414-F3F5B225-5058-4C2D-A5E1-4849CF416F9FQ57301710-BC96CD98-21D1-4E70-ABB1-58878FA7B37BQ57486633-D6F098F6-111C-489E-A8C6-D33CF0DE6EFEQ57760906-96C481FB-D0F4-48D8-9970-3409454C8C54
P2860
The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The pathophysiology of acute m ...... fusion: a continual challenge.
@en
type
label
The pathophysiology of acute m ...... fusion: a continual challenge.
@en
prefLabel
The pathophysiology of acute m ...... fusion: a continual challenge.
@en
P2860
P356
P1476
The pathophysiology of acute m ...... fusion: a continual challenge.
@en
P2093
Bernard J Gersh
Gerd Heusch
P2860
P304
P356
10.1093/EURHEARTJ/EHW224
P577
2016-06-26T00:00:00Z